• About Us
    • Our Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Approach
    • Focus Areas
    • Collaborations
  • Our Science
    • Our Pipeline
    • QLS-111
    • Publications & Posters
  • News and Events
  • Careers
  • Contact Us
  • Skip to main content
Qlaris Bio

Qlaris Bio

Careers Contact Us
News and Events

News and Events

VIEW:

  • All
  • News
  • Event

Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101

NewsMay 18, 2022

Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101  Findings from First-in-Human Study Support Continued Clinical Development of Investigational IOP-lowering Therapy; New Trials Planned as Complementary Glaucoma Treatment and in Rare Pediatric Indication  Wellesley, Mass., May 18, 2022 – Qlaris Bio, Inc. (the “Company” or “Qlaris”), […]

Read More about Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101

Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101

NewsApril 15, 2021

Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational TherapyDesigned to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma -Phase 1/2 Initiation Follows FDA Acceptance of Investigational New Drug (IND) Application- Wellesley, Mass., April 15, 2021 — Qlaris Bio, Inc., a biotechnology company targeting high unmet needs in debilitating ophthalmic […]

Read More about Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101
  • « Go to Previous Page
  • Go to page 1
  • Go to page 2

Qlaris Bio, Inc. © 2023 All Rights Reserved Privacy Policy | Terms of Use | Accessibility Statement

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept